BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Gearing Up For August Approval

 
• By Andrew McConaghie
  
Biomarin
BioMarin needs to persuade payers that a $2-3m price tag for gene therapy is good value compared to conventional therapy • Source: BioMarin
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip